GHRP-2: Growth Hormone Releasing Peptide Research, GH Secretion & Body Composition

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is GHRP-2?

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue with the amino acid sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂. It belongs to the growth hormone-releasing peptide (GHRP) family, a class of synthetic compounds that stimulate growth hormone (GH) release from the anterior pituitary gland by acting on the growth hormone secretagogue receptor type 1a (GHS-R1a), commonly known as the ghrelin receptor.

GHRP-2 was first characterized in the early 1990s as part of a systematic effort by Bowers and colleagues to develop potent GH secretagogues from small peptide scaffolds. Among the GHRPs studied, GHRP-2 emerged as one of the most potent stimulators of GH release on a per-dose basis, earning it a prominent place in growth hormone research over the following decades.

Within the GHRP family, GHRP-2 is frequently described as the “balanced” secretagogue. It produces stronger GH release than ipamorelin, the most selective GHRP, while causing less elevation of cortisol and prolactin than hexarelin, the most potent. This intermediate profile has made GHRP-2 one of the most widely cited GHRPs in clinical and preclinical literature, with research spanning GH deficiency diagnostics, body composition studies, aging physiology, and sleep architecture.

In Japan, GHRP-2 has been approved under the brand name Pralmorelin as a diagnostic agent for evaluating growth hormone deficiency, underscoring its established pharmacological profile in the clinical research community.

Mechanism of Action

GHRP-2 exerts its primary effects through the ghrelin receptor (GHS-R1a), a G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary, as well as in the hypothalamus, hippocampus, and peripheral tissues. Understanding this mechanism requires distinguishing it from the GHRH receptor pathway, as these two systems represent complementary but distinct routes for stimulating GH release.

GHS-R1a Receptor Activation

Upon binding to GHS-R1a, GHRP-2 activates the phospholipase C (PLC) signaling cascade via the G_q/11 alpha subunit. This produces inositol trisphosphate (IP₃) and diacylglycerol (DAG), leading to calcium release from intracellular stores and activation of protein kinase C (PKC). The resulting increase in intracellular calcium triggers GH granule exocytosis from pituitary somatotrophs.

This signaling pathway is distinct from the GHRH receptor mechanism, which operates through adenylyl cyclase and cyclic AMP. Because GHRP-2 and GHRH analogs activate different intracellular cascades that converge on GH release, their co-administration has been investigated for synergistic effects — a topic discussed in detail below.

Hypothalamic Actions

Beyond direct pituitary stimulation, GHRP-2 acts at the hypothalamic level through two complementary mechanisms. First, it stimulates the release of endogenous GHRH from hypothalamic neurons, amplifying the GH signal through the GHRH receptor pathway. Second, it has been observed to attenuate somatostatin release, reducing the primary inhibitory brake on GH secretion. This dual hypothalamic action — enhancing GHRH while suppressing somatostatin — contributes to the robust GH response observed with GHRP-2 in research models.

Appetite and Ghrelin Pathway Effects

Because GHS-R1a is the endogenous receptor for ghrelin, GHRP-2 mimics certain ghrelin-related effects beyond GH release. Research has documented moderate appetite stimulation following GHRP-2 administration, consistent with ghrelin receptor activation in the arcuate nucleus of the hypothalamus. This appetite-stimulating effect is less pronounced than that observed with GHRP-6, which has stronger ghrelin-mimetic properties, but more noticeable than with ipamorelin, which demonstrates greater selectivity for GH release.

Cortisol and Prolactin Modulation

GHRP-2 has been observed to produce modest, transient elevations in cortisol and prolactin levels in published studies. These secondary hormonal effects are dose-dependent and are generally less pronounced than those observed with hexarelin, the most potent GHRP. The mechanism underlying cortisol elevation is thought to involve ACTH stimulation, while prolactin elevation may relate to dopaminergic pathway modulation. Importantly, research indicates that these elevations are typically acute and self-limiting rather than sustained.

Research Applications

GHRP-2 has been investigated across multiple research domains, reflecting both its potent GH-releasing properties and its well-characterized pharmacological profile.

Growth Hormone Deficiency Diagnostics

One of GHRP-2’s most established research applications is in the diagnostic evaluation of GH deficiency. The GHRP-2 stimulation test has been studied as an alternative to insulin tolerance testing (ITT) and arginine stimulation for assessing pituitary GH reserve. Research has indicated that GHRP-2 testing may offer advantages in convenience and safety compared to ITT, which carries risks of hypoglycemia. Studies by Kojima et al. and others have characterized the GH response curve following GHRP-2 administration, establishing reference ranges for diagnostic interpretation.

In Japan, pralmorelin (GHRP-2) is approved specifically for this diagnostic purpose, representing the only regulatory approval for a GHRP compound in any major market.

GH Secretion and the Somatotropic Axis

GHRP-2 has been used extensively as a research tool for studying GH secretion physiology. Studies have examined dose-response relationships, the kinetics of GH release following GHRP-2 administration, and the effects of repeated dosing on pituitary responsiveness. Research by Bowers et al. demonstrated that GHRP-2 produces reliable, dose-dependent GH release across different subject populations, making it a valuable pharmacological tool for probing somatotroph function.

Body Composition Research

Preclinical and limited clinical studies have investigated GHRP-2’s effects on body composition parameters in the context of GH axis activation. Research in animal models has examined changes in lean mass, fat mass, and metabolic markers following chronic GHRP-2 administration. These studies aim to characterize the downstream effects of sustained ghrelin receptor-mediated GH release on tissue-level outcomes.

Aging and Sarcopenia

The age-related decline in GH secretion — known as the somatopause — has been a research focus for GHRPs including GHRP-2. Studies have investigated whether GHRP-2-stimulated GH release can be maintained in aged subjects, where endogenous GH pulsatility is diminished. Research suggests that while GH responses to GHRP-2 are attenuated with age, the peptide retains the ability to stimulate measurable GH release even in elderly subjects, making it a useful research tool for studying age-related changes in the somatotropic axis.

Sleep and Nocturnal GH Secretion

Growth hormone secretion follows a circadian pattern, with the largest endogenous GH pulse occurring during slow-wave sleep. Research has investigated the relationship between GHRP-2 administration and sleep-related GH dynamics. Studies have examined whether GHRP-2 can augment the nocturnal GH pulse and whether this augmentation has measurable effects on sleep architecture. This line of investigation connects to broader research on the relationship between the ghrelin/GH axis and sleep physiology.

Synergy with GHRH Analogs

One of the most consistently reported findings in GHRP-2 research is its synergistic interaction with GHRH analogs such as CJC-1295 and sermorelin. Because GHRP-2 and GHRH analogs activate different receptor pathways (GHS-R1a and GHRHR, respectively) that converge on pituitary GH release, their co-administration produces a GH response significantly greater than either compound alone. Published studies have documented that the combined GH release is not merely additive but truly synergistic, with peak GH levels exceeding the sum of individual responses. This synergy has been investigated as a research model for maximizing endogenous GH production while maintaining physiological regulation.

Comparison with Other GHRPs

The GHRP family includes several peptides that share the GHS-R1a receptor target but differ in potency, selectivity, and secondary effects. The following comparison is based on published research data and is intended to help researchers select the appropriate compound for their study design.

Parameter	GHRP-2	GHRP-6	Hexarelin	Ipamorelin
Chemical Class	Hexapeptide	Hexapeptide	Hexapeptide	Pentapeptide
Primary Receptor	GHS-R1a	GHS-R1a	GHS-R1a	GHS-R1a
GH Release Potency	High	Moderate-High	Highest	Moderate
Cortisol Elevation	Mild-Moderate	Moderate	Significant	Minimal
Prolactin Elevation	Mild-Moderate	Moderate	Significant	Minimal
Appetite Stimulation	Moderate	Strong	Moderate	Minimal
GH Selectivity	Moderate	Low-Moderate	Low	High
Desensitization Risk	Low with pulsatile dosing	Low with pulsatile dosing	Reported with chronic use	Low
Key Research Distinction	Balanced profile; GHD diagnostics (approved in Japan)	Strongest ghrelin-mimetic effects; appetite research	Most potent GH release; cardiac receptor research	Most selective; cleanest hormonal profile

Interpreting the Comparison

GHRP-2 vs. GHRP-6: Both are hexapeptide GH secretagogues with similar structures. GHRP-6 exhibits stronger ghrelin-mimetic properties, resulting in more pronounced appetite stimulation and slightly greater cortisol and prolactin elevation. GHRP-2 produces higher GH release per unit dose while maintaining a cleaner secondary hormonal profile. Researchers studying appetite or ghrelin physiology may prefer GHRP-6, while those focused on GH axis function often select GHRP-2.

GHRP-2 vs. Hexarelin: Hexarelin is the most potent GH secretagogue in the GHRP family but produces the most significant elevations in cortisol and prolactin. Published research has also reported receptor desensitization with chronic hexarelin administration, a concern that appears less prominent with GHRP-2. Additionally, hexarelin has been investigated for cardiac effects through non-GHS-R1a pathways (CD36 receptor), a research area unique among GHRPs. For a detailed examination of hexarelin’s pharmacology, see our hexarelin research guide.

GHRP-2 vs. Ipamorelin: Ipamorelin demonstrates the highest GH selectivity among GHRPs, with minimal effects on cortisol, prolactin, and appetite. However, its GH release potency is lower than GHRP-2. Researchers requiring maximal GH stimulation with acceptable secondary effects typically select GHRP-2, while those requiring a clean hormonal profile choose ipamorelin. For combination research with GHRH analogs, see the CJC-1295 + ipamorelin research guide.

Dosing in Research Models

The following dosing parameters are derived from published preclinical and clinical research. They are presented for reference in research protocol design and do not constitute dosing recommendations for any non-research application.

Parameter	Published Research Range
Route of Administration	Subcutaneous (SC) or intravenous (IV) in clinical studies; intraperitoneal (IP) in animal models
Diagnostic Testing Dose	1 mcg/kg IV (single bolus, GHD evaluation protocol)
Research Dose Range (clinical studies)	100-300 mcg SC per administration
Frequency in Published Protocols	1-3 times daily, typically aligned with natural GH pulse timing
GH Peak Post-Administration	15-30 minutes (varies by route; IV peak is earlier than SC)
Duration of GH Elevation	Approximately 60-90 minutes from administration

Research protocols investigating synergy with GHRH analogs have typically administered GHRP-2 simultaneously or within a narrow time window alongside CJC-1295 (no DAC) or sermorelin. Published studies have noted that timing relative to meals and sleep may influence the magnitude of GH response, consistent with the known interactions between ghrelin signaling, nutritional status, and circadian GH pulsatility.

Reconstitution and Handling

GHRP-2 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before use in research protocols. Proper handling is essential for maintaining peptide integrity and ensuring experimental reproducibility.

Reconstitution Protocol

1. Remove the lyophilized vial from refrigerated storage and allow it to reach room temperature (approximately 15-20 minutes). Do not heat the vial.
2. Clean the vial stopper with an alcohol swab before piercing.
3. Using a sterile syringe, draw the appropriate volume of bacteriostatic water (0.9% benzyl alcohol preserved).
4. Insert the needle through the stopper and direct the stream of water down the inside wall of the vial. Do not inject directly onto the lyophilized pellet, as this can damage the peptide.
5. Allow the powder to dissolve naturally. Swirl gently if needed. Do not shake or vortex — mechanical agitation can denature the peptide and reduce biological activity.
6. The reconstituted solution should be clear and colorless. If particulate matter or cloudiness is observed, the vial should not be used.

Storage and Stability

• Lyophilized (unreconstituted): Store at 2-8°C (refrigerated), protected from light and moisture. Lyophilized GHRP-2 is stable for extended periods under these conditions.
• Reconstituted: Store at 2-8°C. When reconstituted in bacteriostatic water, the solution is generally stable for up to 30 days under refrigeration. Sterile water reconstitutions should be used within a shorter timeframe.
• Long-term storage: For extended storage of lyophilized peptide, -20°C is recommended.
• Avoid: Repeated freeze-thaw cycles, temperatures above 25°C, direct light exposure, and contamination from non-sterile technique.

Purity and Quality Considerations

Research-grade GHRP-2 should meet the following specifications: HPLC purity of 98% or greater, identity confirmed by mass spectrometry (expected MW approximately 817.9 Da), and endotoxin levels within acceptable ranges for the intended research application. Researchers should obtain and review the certificate of analysis (COA) before use. NorthPeptide GHRP-2 is supplied with third-party analytical documentation.

Safety Profile in Published Research

The safety data for GHRP-2 is drawn from published clinical studies, diagnostic use protocols, and preclinical investigations. The following observations are from the research literature and do not constitute a safety assessment for any non-research application.

Observed Effects in Clinical Studies

• Growth hormone elevation: GHRP-2 reliably produces acute GH elevation that is self-limiting, returning to baseline within approximately 2-3 hours. The somatostatin feedback mechanism provides a physiological ceiling on GH levels.
• Cortisol and prolactin: Mild to moderate, transient elevations have been reported. These effects are dose-dependent and generally less pronounced than with hexarelin. Published data indicates that cortisol and prolactin levels return to baseline within 1-2 hours of administration.
• Appetite stimulation: Moderate increases in appetite have been observed, consistent with ghrelin receptor activation. This effect is less intense than with GHRP-6 and typically transient.
• Injection site reactions: Mild, transient reactions at subcutaneous injection sites have been reported in some studies, consistent with other subcutaneously administered peptides.
• Water retention: Some research protocols have noted mild fluid retention, which is consistent with the known effects of GH elevation on sodium and water balance.

Desensitization Considerations

A concern with all GHS-R1a agonists is potential receptor desensitization with chronic use. Published research on GHRP-2 suggests that desensitization is less of a concern than with hexarelin, particularly when pulsatile dosing protocols are employed rather than continuous administration. Studies using intermittent dosing schedules have reported sustained GH responses over extended research periods.

Limitations of Available Safety Data

While GHRP-2 has been studied in human subjects — particularly in diagnostic contexts — the total body of human safety data remains limited compared to approved therapeutics. Long-term safety studies involving chronic administration are sparse. The majority of extended-duration data comes from animal models. Researchers should consider these limitations when designing protocols and interpreting outcomes.

Summary

GHRP-2 occupies a distinct position within the growth hormone secretagogue family as a well-characterized, potent GH-releasing peptide with a balanced pharmacological profile. Its mechanism of action through GHS-R1a — distinct from and synergistic with the GHRH receptor pathway — makes it a versatile research tool for studying GH physiology, pituitary function, and the somatotropic axis.

Key points from the published literature:

• GHRP-2 is one of the most potent and widely studied synthetic GH secretagogues, with an established role in GH deficiency diagnostic testing.
• It acts through the ghrelin receptor (GHS-R1a), producing robust GH release through both direct pituitary stimulation and hypothalamic modulation of GHRH and somatostatin.
• Among the GHRPs, GHRP-2 offers a balanced profile: stronger GH release than ipamorelin, with less cortisol and prolactin elevation than hexarelin.
• Synergistic GH release when combined with GHRH analogs such as CJC-1295 or sermorelin has been consistently demonstrated in published research.
• Research applications span GH deficiency diagnostics, body composition studies, aging and sarcopenia investigation, and sleep-related GH physiology.
• Moderate appetite stimulation and mild secondary hormonal effects (cortisol, prolactin) are well-documented and generally transient.

Researchers selecting among available GHRPs should consider their specific study requirements: ipamorelin for maximum GH selectivity, hexarelin for maximum GH potency, GHRP-6 for ghrelin-pathway and appetite research, and GHRP-2 for a balanced profile suitable for broad GH axis investigation. For GHRH-pathway research, see our guides on sermorelin and tesamorelin.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Laferrère et al.	2005	Clinical Trial	GHRP-2, like ghrelin, increases food intake in healthy men	PMC2824650
Berlanga-Acosta et al.	2017	Review	Synthetic GHRPs: historical appraisal of cytoprotective effects	PMC5392015
Alba et al.	2012	In Vivo	GH response to GHRP-2 in growth hormone-deficient Little mice	PMC3297037
Muccioli et al.	2007	Review	The growth hormone secretagogue receptor: intracellular signaling and regulation	PMC3975427
Kojima & Kangawa	2005	Review	Ghrelin as a regulatory peptide in growth hormone secretion	PMC4190751
Okimura et al.	2001	Clinical Trial	GHRP-2 stimulates GH secretion in GH-deficient patients with mutated GHRH receptor	PubMed 11443201
Mericq et al.	2009	In Vivo	GHRP-2 suppresses vascular oxidative stress in ApoE-/- mice	PMC2795722
Howard et al.	1996	Review	Integrating growth hormone secretagogues into the ghrelin system	PMC2925380

---